Navigation Links
Spring Point Project Names New Members to Board of Directors
Date:6/16/2008

Board members help guide non-profit on path to cure diabetes

MINNEAPOLIS, June 16 /PRNewswire/ -- Spring Point Project, a Minnesota non-profit organization created to expedite the widespread availability of islet tissue for diabetes care, has attracted two well-known experts to its Board of Directors: Steven D. Murphy and Timothy Scott Clark.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071214/CLF057LOGO-b )

Steven D. Murphy is chief executive officer for the National Pork Board. He is responsible for the development and implementation of promotion, research and consumer information initiatives strategically directed toward the issues most critical to the United States pork industry. Murphy, who was selected as the National Pork Board first CEO in 2001, and his staff provide oversight for 43 state pork associations. Prior to the National Pork Board, Murphy led the creation of three start-up companies centered on leading-edge technologies and information management strategies.

Timothy Scott Clark is a senior partner and member of the executive team of CarVal Investors, a global leader in opportunistic value investing. He joined the firm in 1992, and has experience investing in a wide variety of assets. Clark received his MBA from the University of Chicago and his Bachelor of Arts degree from DePauw University. He is active in the community and currently sits on several for-profit and non-profit boards.

"Steve and Tim bring diverse areas of expertise that will add great value to our board and Spring Point Project," says Tom Cartier, president and chairman of the Spring Point Project board. "Steve's knowledge of the pork and biotech industries and Tim's experience in finance and business will be invaluable not only in providing direction for daily operations but also in further development of pig islets to a clinical entity."

Currently, there are about 25 million people in the United States with diabetes, representing approximately eight percent of the population. Diabetes alone represents 11 percent of the nation's health care expenditure.

Spring Point Project works in partnership with the Diabetes Institute for Immunology and Transplantation of the University of Minnesota on the mission to expedite the affordable and widespread availability of islet tissue to diabetes patients. In this partnership, the two organizations provide the science and the source needed to move toward a cure for diabetes. The Diabetes Institute conducts the preclinical and clinical trials, and Spring Point Project builds and operates the biosecure facilities where high-health source pig donors are developed.

The Diabetes Research and Wellness Foundation, a not-for-profit worldwide network based in Washington, D.C., is also part of the partnership with a major $6.2 million grant to Spring Point Project.

To contact Spring Point Project, visit http://www.SpringPointProject.org. To contact the Diabetes Institute for Immunology and Transplantation, visit http://www.diabetesinstitute.org. To contact Diabetes Research & Wellness Foundation, visit http://www.diabeteswellness.net.

Contact:

Molly Kersten

R/P Marketing Public Relations

(419)241-2221

mkersten@r-p.com


'/>"/>
SOURCE Spring Point Project
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
2. Creating the Bionic Woman: Making Nerves Spring Back to Life
3. Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply
4. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
5. MaxCyte to Present at BIO-Europe Spring 2008 Conference
6. Springer publishes anthology with the Nanoethics Group
7. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
10. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
11. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- Champions Oncology, Inc. (NASDAQ: CSBR ), a ... technology solutions and products to personalize the development and ... new cohorts of PDX models to their existing TumorBank. ... product line in hepatocellular cancer, breast cancer, castrate resistant ... cell lung cancer (including EGFR mutation; ALK/ROS1 positive) PDX ...
(Date:2/16/2017)... Feb. 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... influenza study showed that aerosolized KL4 surfactant reduced ... well-established preclinical animal model. The Company believes that ... of evidence that supports the role of KL4 ...
(Date:2/16/2017)... , Feb. 16, 2017 Paradigm Diagnostics ... B financing, adding an additional $3M from New Sciences ... Verde Venture Partners and other strategic partners at the ... further accelerating commercial adoption of their flagship Paradigm Cancer ... expanding the Paradigm cancer registry. Dr. ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, ... Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics ... company focused on identifying inherited disease risk in future generations. In his new ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
Breaking Biology News(10 mins):